Selexipag

Active ingredient: Selexipag

In short: Adult Patients Selexipag tablets are indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. Effectiveness of selexipag tablets was established in a long-term study in adult PAH patients

Forms & strengthsSelexipag tablets are available in the following presentations: 200 mcg [Beige colored, round, film coated tablet, debossed with "S2" on one side and plain on other side] 400 mcg [Pink colored, round, film coated tablet, debossed with "S4" on one side and …
LabelZydus Lifesciences Limited
Label updatedNov 04, 2026

What is Selexipag used for?

Adult Patients

Selexipag tablets are indicated for the treatment of pulmonary arterial hypertension in adults (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Effectiveness of selexipag tablets was established in a long-term study in adult PAH patients with WHO Functional Class II-III symptoms.

Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%) .

Pediatric use information is approved for Actelion Pharmaceuticals US, Inc.'s Uptravi (selexipag) Tablets. However, due to Actelion Pharmaceuticals US, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.

Selexipag dosage

Adult Patients

The recommended starting dosage of selexipag tablets is 200 mcg given orally twice daily. Tolerability may be improved when taken with food .

Increase the dose in increments of 200 mcg orally twice daily, usually at weekly intervals, to the highest tolerated dose up to 1,600 mcg orally twice daily. If a patient reaches a dose that cannot be tolerated, the dose should be reduced to the previous tolerated dose.

Swallow the selexipag tablets whole. Do not split or crush the tablets.

Pediatric use information is approved for Actelion Pharmaceuticals US, Inc.'s Uptravi (selexipag) Tablets. However, due to Actelion Pharmaceuticals US, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.

If a dose of selexipag tablets are missed, patients should take a missed dose as soon as possible unless the next dose is within the next 6 hours.

If treatment is missed for 3 days or more, restart selexipag tablets at a lower dose and then re-titrate.

No dose adjustment of selexipag is necessary for patients with mild hepatic impairment (Child-Pugh class A).

For adult patients with moderate hepatic impairment (Child-Pugh class B), reduce the starting dose of selexipag tablets (200 mcg for adults) to once daily. Increase in increments equal to the starting dose once daily at weekly intervals, as tolerated [see Dosage and Administration (2.1), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

Avoid use of selexipag in patients with severe hepatic impairment (Child-Pugh class C).

Pediatric use information is approved for Actelion Pharmaceuticals US, Inc.'s Uptravi (selexipag) Tablets. However, due to Actelion Pharmaceuticals US, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.

When co-administered with moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox and teriflunomide) in adult patients, reduce the dosing of selexipag to once daily .

Pediatric use information is approved for Actelion Pharmaceuticals US, Inc.'s Uptravi (selexipag) Tablets. However, due to Actelion Pharmaceuticals US, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.

How to take Selexipag — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Inform Patients

To take a missed dose as soon as possible, unless the next dose is within the next 6 hours.

Not to split or crush tablets.

The trademarks referenced are owned by third parties not affiliated with Zydus Pharmaceuticals (USA) Inc.

Manufactured by:

Zydus Lifesciences Ltd.

Ahmedabad, India

Rev.: 11/26

Warnings & precautions

Do not take this medicine if: Hypersensitivity to the active substance or to any of the excipients.

Concomitant use of strong inhibitors of CYP2C8 (e.g., gemfibrozil) .

Should signs of pulmonary edema occur, consider the possibility of associated pulmonary veno-occlusive disease. If confirmed, discontinue selexipag.

Selexipag side effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Selexipag Tablets

Adult Patients

The safety of selexipag tablets has been evaluated in a long-term, placebo-controlled study enrolling 1,156 adult patients with symptomatic PAH (GRIPHON study) . The exposure to selexipag in this trial was up to 4.2 years with median duration of exposure of 1.4 years.

Table 3 presents adverse reactions more frequent on selexipag tablets than on placebo by ≥3%.

Adverse Reaction | Selexipag tablets

N=575 | Placebo

N=577

Headache | 65% | 32%

Diarrhea | 42% | 18%

Jaw pain | 26% | 6%

Nausea | 33% | 18%

Myalgia | 16% | 6%

Vomiting | 18% | 9%

Pain in extremity | 17% | 8%

Flushing | 12% | 5%

Arthralgia | 11% | 8%

Anemia | 8% | 5%

Decreased appetite | 6% | 3%

Rash | 11% | 8%

These adverse reactions are more frequent during the dose titration phase.

Hyperthyroidism was observed in 1% (n=8) of patients on selexipag tablets and in none of the patients on placebo.

Laboratory Test Abnormalities

Hemoglobin

In a Phase 3 placebo-controlled study in adult patients with PAH, mean absolute changes in hemoglobin at regular visits compared to baseline ranged from −0.34 to −0.02 g/dL in the selexipag group compared to −0.05 to 0.25 g/dL in the placebo group. …

Drug interactions

Concomitant administration with gemfibrozil, a strong inhibitor of CYP2C8, doubled the exposure to selexipag and increased exposure to the active metabolite by approximately 11-fold. Concomitant administration of selexipag with strong inhibitors of CYP2C8 (e.g., gemfibrozil) is contraindicated .

Concomitant administration of selexipag tablets with clopidogrel, a moderate inhibitor of CYP2C8, had no relevant effect on the exposure to selexipag and increased the exposure to the active metabolite by approximately 2.7-fold . Reduce the dosing of selexipag to once daily in adult patients on a moderate CYP2C8 inhibitor .

Pediatric use information is approved for Actelion Pharmaceuticals US, Inc.'s Uptravi (selexipag) Tablets. However, due to Actelion Pharmaceuticals US, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information.

Concomitant administration with an inducer of CYP2C8 and UGT1A3 and 2B7 enzymes (rifampin) halved exposure to the active metabolite. Increase selexipag up to twice the dose when co-administered with rifampin. Reduce selexipag when rifampin is stopped .

About this medicine

Selexipag tablets contains selexipag, a prostacyclin receptor agonist. The chemical name of selexipag is 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N(methylsulfonyl) acetamide. It has a molecular formula of C26H32N4O4S and a molecular weight of 496.62. Selexipag has the following structural formula:

Selexipag is an off white to pale yellow crystalline powder that is practically insoluble in water. In the solid state selexipag is very stable, is not hygroscopic, and is not light sensitive.

Depending on the dose strength, each round film-coated tablet for oral administration contains 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,000 mcg, 1,200 mcg, 1,400 mcg, or 1,600 mcg of selexipag. The tablets include the following inactive ingredients: corn starch, colloidal silicon dioxide, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, microcrystalline cellulose and magnesium stearate. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ff660787-880f-4f2b-baac-fd2dbfcd79c2. Read the full official label on DailyMed.

Related medicines

Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone